Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranquillo 2: Ritlecitinib in Adults With Nonsegmental Vitiligo
jRCT2031230468Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in nonsegmental vitiligo (3 arms), sponsored by Pfizer. Started Dec 2023; status: active, not recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on jRCT2031230468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230468.